Caroline H Williams-Gray

List of Publications by Year
in descending order

41 papers	6,686 citations	159585 30 h-index	289244 40 g-index
43 all docs	43 docs citations	43 times ranked	6644 citing authors

#	Article	IF	Citations
1	<scp>GBA</scp> and <scp>APOE</scp> Impact Cognitive Decline in Parkinson's Disease: A 10â€Year Populationâ€Based Study. Movement Disorders, 2022, 37, 1016-1027.	3.9	45
2	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
3	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinsonâ€™s disease. Nature Genetics, 2021, 53, 787-793.	21.4	82
4	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinsonâ€™s Disease in the ICICLE-PD Cohort. Journal of Parkinson's Disease, 2021, 11, 1297-1308.	2.8	11
5	Motor Complications in Parkinson's Disease: 13â€Year Followâ€up of the CamPaIGN Cohort. Movement Disorders, 2020, 35, 185-190.	3.9	39
6	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinsonâ€™s Disease: The ICICLE-PD Study. Journal of Parkinson's Disease, 2020, 10, 193-206.	2.8	34
7	Cerebrospinal Fluid Cytokines and Neurodegenerationâ€Associated Proteins in Parkinson's Disease. Movement Disorders, 2020, 35, 1062-1066.	3.9	33
8	Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2020, 87, 473-488.	4.1	58
9	A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 673-674.	1.9	9
10	Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 695-702.	1.9	48
11	The clinical heterogeneity of Parkinson's disease and its therapeutic implications. European Journal of Neuroscience, 2019, 49, 328-338.	2.6	137
12	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	3.9	122
13	Genetic risk of Parkinson disease and progression:. Neurology: Genetics, 2019, 5, e348.	1.9	109
14	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2019, 34, 1244-1250.	2.7	31
15	The motor and cognitive features of Parkinsonâ€™s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology, 2018, 265, 1789-1794.	3.6	11
16	Stability of mild cognitive impairment in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 648-652.	1.9	88
17	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
18	The role of highâ€field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Movement Disorders, 2017, 32, 510-525.	3.9	92

#	Article	IF	Citations
19	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
20	The Genetic Basis of Cognitive Impairment and Dementia in Parkinsonâ€™s Disease. Frontiers in Psychiatry, 2016, 7, 89.	2.6	46
21	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism and Related Disorders, 2016, 27, 47-53.	2.2	133
22	Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Annals of Neurology, 2016, 80, 674-685.	5.3	226
23	Mild Cognitive Impairment and Parkinsonâ€™s Disease - Something to Remember. Journal of Parkinson's Disease, 2015, 4, 651-656.	2.8	22
24	Glucocerebrosidase mutations influence the natural history of Parkinsonâ€™s disease in a community-based incident cohort. Brain, 2013, 136, 392-399.	7.6	266
25	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1258-1264.	1.9	534
26	Neuropsychological Features of Early Cognitive Impairment in Parkinsonâ€™s Disease. Advances in Biological Psychiatry, 2012, , 84-102.	0.2	1
27	From Molecule to Clinic and Community for Neurodegeneration: Research to Bridge Translational Gaps. Journal of Alzheimer's Disease, 2012, 33, S385-S396.	2.6	5
28	Addenbrooke's Cognitive Examinationâ€Revised for mild cognitive impairment in Parkinson's disease. Movement Disorders, 2012, 27, 1173-1177.	3.9	38
29	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disorders, 2012, 27, 312-315.	3.9	56
30	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	3.9	1,908
31	The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1112-1118.	1.9	200
32	Catecholâ€Oâ€methyltransferase val158met and cognitive function in Parkinson's disease. Movement Disorders, 2010, 25, 2550-2554.	3.9	44
33	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinsonâ€™s Disease. Journal of Neurology, 2009, 256, 493-498.	3.6	141
34	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 2009, 132, 2958-2969.	7.6	842
35	Attentional control in Parkinson's disease is dependent on COMT val158met genotype. Brain, 2008, 131, 397-408.	7.6	165
36	Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nature Clinical Practice Neurology, 2007, 3, 250-251.	2.5	1

#	Article	IF	Citations
37	CatecholO-Methyltransferase val¹⁵⁸met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease. Journal of Neuroscience, 2007, 27, 4832-4838.	3.6	175
38	Tau and Î±â€synuclein in susceptibility to, and dementia in, Parkinson's disease. Annals of Neurology, 2007, 62, 145-153.	5.3	256
39	Cognitive Deficits and Psychosis in Parkinson???s Disease. CNS Drugs, 2006, 20, 477-505.	5.9	115
40	No alterations in Î±-synuclein gene dosage observed in sporadic Parkinson's disease. Movement Disorders, 2006, 21, 731-732.	3.9	6
41	The genetics of behavior and cognition in Parkinsonâ€™s disease. , 0, , 25-39.		0